IGF-1 LR3
Animal / preclinicalWADA prohibitedAlso known as: Long R3 IGF-1
Community-reported ranges are anecdotal and not clinically validated. Evidence grade shown reflects the strength of available human data. Not a prescription. Legal status varies by country and changes over time; verify locally.
Overview
A modified, long-acting form of IGF-1 — one of the most anabolic signalling molecules in the body — engineered to stay active far longer than the native hormone. That potency is the appeal in bodybuilding and also the risk: hypoglycaemia and indiscriminate tissue growth are real, and it is WADA-prohibited.
Mechanism
Activates IGF-1 receptors driving cell growth; the LR3 modification extends half-life and reduces binding-protein inactivation, amplifying exposure.
Evidence
The anabolic mechanism is established biology, but physique use has no human trials, and hypoglycaemia is a documented, meaningful hazard.
Community-reported information
Community reports vary. Anecdotal, unvalidated and potentially dangerous; general information only.
General information only, not tailored to you and not a recommendation. Some regions withhold this entirely.
Half-life
~20–30 hours (LR3 variant).
Storage
Refrigerate; sensitive to degradation.
Commonly reported side effects
- Hypoglycaemia
- Localised tissue growth
- Headache
Legal status by region
- USNot FDA-approved for human use.
- AUPrescription-only; import controlled.
Legal status changes over time; verify locally before relying on this.
Citations
- IGF-1 researchPubMed
- WADA Prohibited ListWADA